Testing a multigene signature of prostate cancer death in the Swedish watchful waiting cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 7, 2008, Pages 1682-1688

  Mucci, Lorelei A ^a,b,c   Pawitan, Yudi ^f   Demichelis, Francesca ^a,c,g,h   Fall, Katja ^f   Stark, Jennifer R ^a,b   Adami, Hans Olov ^b,f   Andersson, Swen Olof ⁱ   Andrén, Ove ⁱ   Eisenstein, Anna ^a   Holmberg, Lars ^j,k   Huang, Wei ^a,c,l   Kantoff, Philip W ^c,d   Kim, Robert ^a   Perner, Sven ^a,c,g,m   Stampfer, Meir J ^a,b,c   Johansson, Jan Erik ⁱ   Rubin, Mark A ^a,c,d,e,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h ITC IRST   (Italy)

ⁱ ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^j UPPSALA UNIVERSITY   (Sweden)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^m UNIVERSITY OF ULM   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER SIZE; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GLEASON SCORE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SWEDEN; WATCHFUL WAITING;

AGED; DNA, NEOPLASM; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PHENOTYPE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SWEDEN; TIME FACTORS;

EID: 53549123026     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0044     Document Type: Article

References (31)

1. Ferlay J, Pisani P, Parkin D. GLOBOCAN 2002: cancer incidence, mortality, and prevalence worldwide. IARC CancerBase No. 5 version 2.0. Lyon: IARC Press; 2004.
2. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
3. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.
4. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97:1248-53.
5. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
6. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
7. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
8. Ciatto S, Gervasi G, Bonardi R, et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 2005;41:411-5.
9. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
10. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
11. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
12. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-8.
13. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715-7.
14. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor β1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-9.
15. Bismar TA, Demichelis F, Riva A, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006;8:59-68.
16. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
17. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006;175:1337-40.
18. Kim R, Demichelis F, Tang J, et al. Internet-based Profiler system as integrative framework to support translational research. BMC Bioinformatics 2005;6:304.
19. Rubin MA, Bismar TA, Andren O, et al. Decreased α-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev2005;14:1424-32.
20. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
21. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 1989;142:1254-8.
22. Humphrey P, Vollmer RT. The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis. Hum Pathol 1988;19:411-8.
23. Anderson PK, Borgan O, Gill RD, Keidling N. Statistical models based on counting processes. New York: Springer-Verlag; 1993.
24. Rosthoj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 2004;74:69-75.
25. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
26. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003;169:1320-4.
27. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 2003;170:S42-6; discussion S46-7.
28. Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among men with conservatively treated localized prostate cancer. Br J Cancer 2007;95:1186-94.
29. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
30. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-7.
31. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:526-32.